FAQ: Lantern Pharma's predictBBB.ai AI Tool for CNS Drug Development
Summary
Lantern Pharma has launched predictBBB.ai, an AI-driven tool that predicts blood-brain barrier permeability for small-molecule drugs with 94% accuracy, aiming to overcome a major challenge in CNS therapeutic development and accelerate drug discovery.
What is predictBBB.ai and what does it do?
predictBBB.ai is an AI-driven module developed by Lantern Pharma that predicts blood-brain barrier permeability for small-molecule drugs with high accuracy, helping researchers identify compounds that can effectively cross this critical barrier.
How accurate is predictBBB.ai in its predictions?
The tool achieves 94% prediction accuracy, with 95% sensitivity and 89% specificity, based on real-time ensemble machine learning algorithms.
Why is predicting blood-brain barrier permeability important for drug development?
Crossing the blood-brain barrier is one of the pharmaceutical industry’s most persistent challenges, as traditionally only 2-6% of small molecules manage to penetrate this barrier, making accurate prediction crucial for developing effective CNS therapeutics.
How does predictBBB.ai work technically?
The platform is powered by Lantern’s vast molecular features data lake and ensemble machine learning algorithms, which analyze billions of molecular features to provide real-time predictions of BBB permeability.
Is predictBBB.ai publicly accessible and what is its pricing model?
Yes, the tool is publicly accessible through a freemium model, making it available to researchers while aiming to drive adoption and strategic partnerships.
What other AI modules is Lantern Pharma developing?
Lantern hosts additional predictive and analytical modules in development, leveraging its large-scale data infrastructure and algorithmic approach beyond the predictBBB.ai platform.
What recent clinical development milestone has Lantern Pharma achieved?
Lantern Pharma subsidiary Starlight Therapeutics has secured FDA IND clearance for its Phase Ib/IIa trial combining STAR-001 (LP-184) and spironolactone in recurrent glioblastoma multiforme.
Where can I access more information about Lantern Pharma and its developments?
The latest news and updates relating to Lantern Pharma (NASDAQ: LTRN) are available in the company’s newsroom at https://ibn.fm/LTRN.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 167254